Excel Industries share price: Buy call, FY26 results

Stock in focus: Excel Industries on 25 September 2026

Excel Industries Ltd. (NSE: EXCELINDUS, BSE: 500650, ISIN: INE369A01029) was quoted at ₹946.00 on NSE, down ₹4.00 (0.42%), in the snapshot timestamped 25 September 2026, 04:06. On BSE, the same feed showed ₹949.30, with a previous close of ₹949.55.

Multiple live-price snippets in the data also show other intraday prints for the stock, including ₹1,002.00 (-2.61%) and a separate Q&A-style line showing ₹1,031.4 as a “current share price”. These differences reflect that the figures are captured at different times or from different market snapshots.

“Buy” view and the stated buy zone

The provided tracker indicates that experts maintained a “Buy” rating for Excel Industries. It also notes the stock entered a Buy zone on 14 Aug ’26 at ₹1,013.65.

From that entry point, the same tracker shows the price moved -₹67.65 (-6.67%). With the stock later quoted around the mid-₹900s in the 25 September snapshot, the near-term move presented in the dataset remains negative versus the mentioned buy-zone level.

Key price levels and trading range mentioned

Another market snapshot included today’s high of ₹1,075.2 and today’s low of ₹998.75. It also listed a 52-week high of ₹1,264.9 and a 52-week low of ₹801.

Because the dataset contains more than one “live” quote and range snapshot, readers should treat these as point-in-time indicators rather than a single consolidated tape.

Company profile and operating segments

Excel Industries is classified under Chemicals, with the industry tagged as Pesticides & Agrochemicals. The description in the dataset says the company manufactures agrochemical intermediates, phosphates, speciality chemicals, biocides and pharma products, and undertakes R&D for custom-made products.

The company also has an environmental focus in the material provided, including an initiative to convert Municipal Solid Waste (MSW) into Organic Soil Conditioner.

Exchange filings: credit rating and quarterly results

Two regulatory updates highlighted in the text relate to standard exchange disclosures under SEBI regulations:

• Under Regulation 30 of SEBI (LODR), the company informed that CRISIL reaffirmed ratings on bank facilities. The long-term bank facilities were reaffirmed at “CRISIL A+/Stable” and the short-term bank facilities at “CRISIL A1”.
• Under Regulation 33 of SEBI (LODR), the company said its board approved unaudited financial results for the quarter ended 30 June 2026, which were reviewed and recommended earlier by the audit committee. The update referenced an auditor-issued Limited Review Report.

FY26 performance and management commentary cited

The dataset includes an FY26 operating performance reference: net operating revenues of INR 1,094 crore for FY26.

It also captures management framing around growth and capital allocation, including:

• Standalone Q4 revenue of INR 281 crore, stated as up 13% YoY.
• A consolidated cash position around INR 1,100 crore.
• A stated strategic emphasis toward higher-value performance chemicals, including biocides and phosphonates, alongside core yellow-phosphorus derivatives.
• A reference to recent additions, including a 2,530 tpa biocides line, a new Rabale R&D centre, and planned capex over the next two to three years aimed at margin improvement.

Dividend recommendation mentioned

A corporate action update in the provided text says the board, at its meeting on 22 May 2026, recommended a final dividend of ₹13.75 per equity share (275%), subject to shareholder approval.

Shareholding snapshot (June 2026)

The shareholding breakup in the dataset is tagged to June 2026. Promoters were shown at 51.86%, with the remaining held by institutions and the public.

A separate holding trend table in the text shows promoters moving from 52.69% (Mar 2026) to 51.86% (Jun 2026).

Valuation and size metrics included in the snapshot

One market dashboard in the dataset reported the following snapshot metrics:

Other lines in the dataset show market cap values at different times, including ₹1,210.93 crore (as of 23 September 2026) and ₹1,201 crore on another snapshot, reinforcing that these are time- and price-dependent.

Market impact: what the data points imply

For investors tracking Excel Industries, the immediate market signal in the provided data is the combination of a “Buy” rating label and a price that is below the cited buy-zone entry level of ₹1,013.65. At the same time, corporate disclosures cited in the text point to balance-sheet strength (with a reported ~₹1,100 crore consolidated cash position) and a credit profile that CRISIL reaffirmed at A+/Stable for long-term facilities.

The financial performance references - including FY26 net operating revenues of ₹1,094 crore and the stated Q4 standalone revenue of ₹281 crore - provide concrete anchors for comparing the company’s operational scale against valuation snapshots such as P/E and market capitalisation.

Analysis: why these updates matter for Excel Industries

The CRISIL reaffirmation matters because it signals continuity in the company’s assessed credit quality for bank facilities, which can influence funding costs and lender comfort. The Regulation 33 update on unaudited quarterly results confirms that the company has completed the required governance steps through the audit committee and board process for the June 2026 quarter.

Separately, the management commentary included in the dataset outlines a strategy tilt toward higher-value performance chemicals and capacity additions such as the 2,530 tpa biocides line and a Rabale R&D centre. While the text does not quantify the margin impact, it clearly links capex planning over the next two to three years to an internal goal of improving profitability.

Conclusion

Excel Industries traded around ₹946 on NSE in the cited 25 September 2026 snapshot, with the dataset showing a continued Buy label and a price still below the noted 14 Aug 2026 buy-zone level. Key items for investors to track from the provided information include the CRISIL A+/Stable and A1 reaffirmation, the board-approved June 2026 quarter unaudited results, and the company’s stated focus on performance chemicals backed by capacity additions and planned capex over the next few years.